Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. - Xie J; Cao J; Wang JF; Zhang BH; Zeng XH; Zheng H; Zhang Y; Cai L; Wu YD; Yao Q; Zhao XC; Mao WD; et al. (Breast cancer research and treatment, 2018)